Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Bid/Ask

<< Previous

Bullboard Posts

Next >>

Comment by RPINVESTOR1on Oct 24, 2024 7:17am

48 Views

Post# 36279767

RE:RE:RE:RE:RE:RE:RE:Bid/Ask

Ingiboy:-

He doesn't have the money to develop the Company in any event. The change to 75% however does not change the fact that he may try to sell the assets to another entity (owned by himself) for peanuts and pay Replicel shareholders 75% of peanuts.

<< Previous

Bullboard Posts

Next >>

Boeing workers end strike, return to work